Research Analysts Issue Forecasts for QNRX Q1 Earnings

Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) – Equities research analysts at Zacks Research issued their Q1 2026 earnings per share (EPS) estimates for Quoin Pharmaceuticals in a research note issued on Wednesday, April 15th. Zacks Research analyst M. Marin expects that the company will earn ($1.80) per share for the quarter. The consensus estimate for Quoin Pharmaceuticals’ current full-year earnings is ($2.05) per share. Zacks Research also issued estimates for Quoin Pharmaceuticals’ Q2 2026 earnings at ($1.86) EPS, Q3 2026 earnings at $1.92 EPS, Q4 2026 earnings at ($1.93) EPS and FY2026 earnings at ($7.51) EPS.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a report on Monday, December 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Quoin Pharmaceuticals has a consensus rating of “Sell”.

Quoin Pharmaceuticals Stock Performance

QNRX stock opened at $6.58 on Friday. The stock has a fifty day moving average of $7.74 and a 200-day moving average of $10.98. Quoin Pharmaceuticals has a fifty-two week low of $5.27 and a fifty-two week high of $41.80. The company has a market capitalization of $11.84 million, a price-to-earnings ratio of -0.19 and a beta of 1.61.

Quoin Pharmaceuticals (NASDAQ:QNRX) last released its earnings results on Friday, March 27th. The company reported ($14.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($6.42) by ($8.38).

Hedge Funds Weigh In On Quoin Pharmaceuticals

Large investors have recently made changes to their positions in the stock. GAMMA Investing LLC grew its position in shares of Quoin Pharmaceuticals by 649.6% in the fourth quarter. GAMMA Investing LLC now owns 2,084 shares of the company’s stock valued at $30,000 after purchasing an additional 1,806 shares in the last quarter. Simplify Asset Management Inc. purchased a new stake in Quoin Pharmaceuticals during the 4th quarter worth about $252,000. AIGH Capital Management LLC bought a new position in Quoin Pharmaceuticals in the 4th quarter worth about $712,000. ADAR1 Capital Management LLC bought a new position in Quoin Pharmaceuticals in the 4th quarter worth about $840,000. Finally, Boothbay Fund Management LLC purchased a new position in Quoin Pharmaceuticals during the 4th quarter valued at about $863,000. 8.63% of the stock is owned by institutional investors.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc The company was founded in 2018 and is based in Ashburn, Virginia.